在头部和部状细胞癌中预测治疗反应的ctDNA:系统性审查
Oliver Jones1, Sumrit Bola2, Stuart C Winter3
1Medical Student, School of Medicine and Biomedical Sciences, Medical Sciences Division, University of Oxford, Oxford, UK.
The Laryngoscope
|July 17, 2025
概括
血循环瘤DNA (ctDNA) 显示出对监测HPV阳性和HPV阴性头癌的前景. 虽然ctDNA监测在检测复发方面具有很高的负预测值,但为了强大的临床应用,需要进一步标准化.
科学领域:
- 在瘤学瘤学.
- 分子诊断学 分子诊断
- 生物标志物 生物标志物
背景情况:
- 头部和部状细胞癌 (HNSCC) 是一个重要的全球健康问题.
- 人类乳头瘤病毒 (HPV) 状态是HNSCC的关键预后因素.
- 血循环瘤DNA (ctDNA) 是癌症管理的新兴生物标志物.
研究的目的:
- 评估血ctDNA在预测HPV阳性和HPV阴性HNSCC治疗反应中的作用.
- 评估ctDNA作为HNSCC患者监测工具的有用性.
主要方法:
- 对Medline,PubMed,Cochrane和EMBASE数据库进行系统的文献审查.
- 在选1026篇文章后,包括18项研究.
- 使用REMARK指南和叙事数据合成进行质量评估.
主要成果:
- ctDNA监测显示,在检测残留或复发性疾病方面,具有很高的负预测值 (91.7%).
- 持续呈阳性ctDNA与更糟糕的结果相关,尽管积极的预测值有所不同.
- 大多数研究只关注HPVctDNA,使用不同的检测方法.
结论:
- 血ctDNA具有在HPV阳性和HPV阴性HNSCC中进行监测的潜力.
- 需要更好地遵守报告准则,以促进元分析和临床实施.
- 对ctDNA检测和报告的标准化对于可靠的应用至关重要.
更多相关视频
相关概念视频
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K